Precefi at the 14th Annual Octane Ophthalmology Tech Forum
Precefi joined the 14th Annual Octane Ophthalmology Tech Forum, where CMO Dr. Ehsan Sadri moderated two expert panels on the future of ophthalmic care.
The Enrollment Challenge in Hidradenitis Suppurativa Clinical Trials
HS trials rarely fail because of the science. They fail at the site. Learn how a specialized dermatology SMO solves the enrollment, retention, and assessment challenges unique to HS programs.
Cataract Awareness Month
Cataracts are the leading cause of vision loss in the United States and the primary ...
Hidradenitis Suppurativa (HS) Week
Closing the gap between symptom and diagnosis starts with awareness and changes through research. Our ...
June is Acne Awareness Month
Every new Acne treatment starts with research. In honor of June Acne Awareness Month, Precefi ...
Molluscum Contagiosum: The Unmet Need for a Safe, Effective Treatment
Molluscum contagiosum affects an estimated 6 million Americans each year, predominantly children between the ages of 1 and 10. Despite two FDA approvals since 2023, a meaningful clinical gap remains and the practice patterns that have long defined pediatric MC management have not yet caught up with the science.
Precefi Presents at the 25th ESPD Congress in Padova, Italy
Precefi, Inc. is pleased to announce that its poster, "Need for a Tolerable and Efficacious ...
AAD2026 in Review
Precefi at AAD2026 in Denver - Highlights from the Annual Meeting.
Enrollment Without Compromise: The Case for Latin American Dermatology Sites in High-Quality Clinical Trials
Latin American dermatology sites offer some of the fastest enrollment timelines in the world, but data quality concerns have kept many sponsors on the sidelines. Read Precefi's position paper to learn why Latin America is no longer a risk to be managed, but an advantage to be leveraged.
